Trial Profile
An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 12 Nov 2018 Results (n=70, newly diagnosed Multiple-myeloma) published in the European Journal of Cancer
- 02 Jul 2018 Status changed from active, no longer recruiting to completed.